Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILOBONE
2024-512468-71-00Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iloprost in proximal humerus fracture (PHF) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Safety and toxicity of Iloprost. Started Nov 2024; status: completed.
02
Drugs
iloprost
03
Conditions
proximal humerus fracture (PHF)
Beyond the preview
Go deeper on 2024-512468-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512468-71-00.